Cara Therapeutics | CARA - Des Atouts





Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
Alterity Therapeutics Limited AUD 37.98M 15.78M 2025-12
Cara Therapeutics USD 32.07M 6.95M 2025-12
Cassava Sciences USD 108.37M 9.99M 2026-03
Chugai Pharma JPY 2.27T 203.49B 2026-03
Cipla INR 424.96B 23.32B 2026-03
Clal Biotechnology ILS 158.39M 24.3M 2023-12
Compugen USD 145.86M 10.71M 2026-03
CSL USD 37.9B 1.5B 2025-12
Grifols EUR 23.15B 142.7M 2025-12
Halozyme Therapeutics USD 2.67B 147.4M 2026-03
J&J USD 200.89B 1.68B 2026-03
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Pacira USD 1.21B 56.38M 2026-03
Pfizer USD 207.62B 542M 2026-03
RedHill Biopharma USD 25.34M 6.97M 2025-12
Supernus Pharmaceuticals USD 1.5B 48.08M 2026-03
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12